Wire · opportunities
Clinical trial AI race shifts from automation to integrated platforms < Life science < Article
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
AI in clinical trials is transitioning from automating specific tasks to building integrated platforms that connect workflows and support decision-making throughout drug development, with agentic AI coordinating complex processes. The market, led by companies like Medidata and IQVIA, is expected to grow rapidly, especially in Asia-Pacific due to clinical trial outsourcing and healthcare digitalisation.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You must pivot from building isolated AI tools to integrated platforms that link clinical trial workflows and decision points. Medidata and other leaders already own vast clinical datasets, so your entry hinges on cooperating or out-executing their platform reach.
◆ Coverage
1 source · 16 Oct 2026
◆ Related on Wire
◆ Topics